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In the previous issue of Breast Cancer Research, Lagadec 
and colleagues [1] used breast cancer cell line models to 
examine the self-renewal and cell cycle properties of 
cancer cells that survive during the course of fractionated 
sublethal radiation. Previous studies from the same group 
and others have demonstrated enrichment or resistance 
of cancer-initiating cells (CICs) during the course of 
fractionated radiation [2,3]. Th  e current report demon-
strates that the enriched CICs are capable of enhanced 
self-renewal for three generations compared with CICs 
from non-irradiated cells. Contrary to non-irradiated 
CICs, which are non-proliferating and are predominantly 
in the G0 phase of the cell cycle, radiation mobilizes CICs 
from a quiescent to a proliferative state (G2 phase). 
Whether CICs undergo similar cell cycle changes in vivo
upon radiation and whether cycling CICs become 
susceptible to drugs targeting cells moving through G2
phase remain to be determined.
Cancer cells expressing the cell surface marker CD44 
but not CD24 (CD44+/CD24−/low) were the ﬁ  rst described 
breast cancer CICs [4]. Subsequent studies have 
identiﬁ  ed additional phenotypic or functional markers or 
both to characterize CICs: elevated levels of aldehyde 
dehydrogenase (ALDH1+) [5], lower levels of proteosome 
activity [6], enhanced PKH26 dye-retaining capacity [7], 
CD24high/CD49Fhigh/Delta-notch-like EGF (epidermal 
growth factor) repeat-containing transmembrane (DNER)
high [7], CD24high/CD49Fhigh/Delta-like 1 (DLL1)high [7], 
CD49F+/DLL1high/DNERhigh, and expression of a mammo-
sphere signature, including low expression of claudin [8]. 
CD44+/CD24− CICs and non-CD44+/CD24− cells 
expressing diﬀ  erent levels of these markers have been 
tested in in vitro (mammosphere) and in vivo (tumori-
genicity in NOD/SCID [non-obese diabetic/severe 
combined immunodeﬁ   ciency disease] mice) assays. 
CD44+/CD24−/ALDH1+ cells display the highest level of 
CIC activity in tumorigenicity assays compared with 
CD44+/CD24− or ALDH1+ cells [5]. Lagadec and 
colleagues [1] observed a subpopulation of CD44+/
CD24−/low cells with low proteosome activity, although 
this speciﬁ  c subpopulation was not characterized further 
for stemness. Although these studies are beginning to 
reﬁ   ne CICs into distinct subgroups, the remaining 
question is which of the pheno  typically distinct CICs are 
responsible for chemotherapy resistance and radiation 
resistance and organ-speciﬁ   c metastasis. Also, it is 
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Identifi  cation and characterization of cancer-initiating 
cells (CICs) enriched for stem cell-like functions and 
the establishment of a link between CICs and tumor 
recurrence, chemotherapy resistance and radiation 
resistance, and metastasis have been the focus of 
cancer research for the last eight years. Although 
this fi  eld has its share of controversies, it is becoming 
apparent that cells isolated from recurrent or residual 
tumors or both are enriched for cancer cells that have 
a specifi  c phenotype compared with heterogeneous 
cells in the primary tumor. Enrichment of CICs in 
tumors subjected to radiation therapy could be due 
in part to the delivery of sublethal doses of treatment 
and the effi   cient radical scavenging system within CICs. 
Sublethal doses of radiation are suffi   cient to induce 
senescence of non-CICs while forcing CICs to gain 
several new properties related to cell cycle progression 
in addition to maintaining or enhancing stem cell 
characteristics of pre-treatment CICs. Characterizing 
pathways responsible for the increase in CICs after 
therapy and exploiting the unique characteristics 
of therapy-resistant CICs for developing targeted 
therapies are becoming a central focus of research in 
the rapidly evolving fi  eld of CICs.
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© 2010 BioMed Central Ltdunclear whether the above markers can identify CICs for 
all intrinsic subtypes of breast cancer [9] or whether 
these markers favor characteriza  tion of CICs derived 
from the basal subtype or the HER2+ subtype of breast 
cancer [10,11].
CD44+/CD24−/low cells are generally enriched in basal 
subtype breast cancers as well as in cell lines that have 
undergone epithelial-to-mesenchymal transition [10,12]. 
In contrast, luminal type breast cancers that express 
estrogen receptor-alpha (ERα) contain less than 1% 
CD44+/CD24−/low cells [10]. Lagadec and colleagues [1] 
were able to demonstrate enrichment of CD44+/CD24− 
cells upon fractionated radiation of ERα+ breast cancer 
cell lines MCF-7 and T47-D. A signiﬁ  cant number of 
enriched cells retained PKH26 dye and contained low 
proteosome activity compared with non-irradiated cells 
or cells with high proteosome activity. Th  us, radiation-
resistant cells display three characteristics of CICs: 
CD44+/CD24−/low, low proteosome, and PKH26+. Interest-
ingly, enriched cells from T47-D cells, but not from 
MCF-7 cells, displayed enhanced self-renewal capacity 
for three generations, suggesting diﬀ   erences in CICs 
between ERα breast cancer cell lines. Both MCF-7 and 
T47-D cells represent luminal type A breast cancer, 
which generally belongs to a favorable prognostic 
subgroup [13]. However, the two cell lines diﬀ  er in their 
p53 mutation status; T47-D cells contain mutant p53, 
whereas p53 is wild-type in the MCF-7 cells [14]. Based 
on the previously described role of p53 in cancer stem 
cells in mouse models [15], it is tempting to speculate 
that p53 status is one of the factors that determine the 
self-renewal capacity of cancer cells that survive a 
sublethal dose of radiation. It is important to emphasize 
that the enrichment of CICs was observed only upon 
exposure to a sublethal dose of radiation. Th  erefore, 
similar enrichment of CICs may not occur in the clinical 
setting unless a signiﬁ  cant fraction of cancer cells receive 
a sublethal dose or contain a p53 mutation or both. In 
this respect, recent clinical trials have demon  strated 
signiﬁ   cant survival beneﬁ   ts of radiation therapy for 
breast cancer patients [16]. Further optimization of 
radiation delivery to avoid exposure to sublethal doses 
may lead to increased beneﬁ  ts of radiation therapy.
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